BIO 2024 New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration
| June 3- 6, 2024
|
Overview:
Join Outcome Capital’s Dr. Paul Mieyal at Bio 2024 in San Diego on June at 11:00 AM, where he will be a panelist for the New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration session. This session addresses the opioid crisis head-on by exploring how the NIH, small biotech, biopharma, and VCs can rejuvenate CNS & pain innovation. The session will focus on pioneering strategies, boosting investment, and fostering public-private partnerships to fuel next-gen pain therapeutics and address this critical health need. |
News
Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability
Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON–(BUSINESS WIRE)-July 8, 2025-Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients […]
Read MoreResources
Outcome Capital Life Science Market Pulse, May 2025
Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
